Advanced Therapies Journal was first published in 2018 as pharmacogenomics and Omics technologies Journal and in 2023 reviewed for optimization and reformed to advanced therapies journal. Now ATJ is a premium home for the publication of interdisciplinary research on the next-generation of therapeutics and advanced therapies. The articles selected for the Editors' Choice are representative of the key topics that the journal publishes, including targeted drug delivery; drug discovery; cellular, genetic, and immunotherapies; personalized and precision medicines; theranostics; omics technologies, tissue engineering, pharmacology; toxicology, and highlight work done by researchers from across the globe.
Publisher:
AmitisGen TECH Dev Group
Editor-in-Chief:
Dr. Sina Salari
Director-in-Charge:
Dr. Farnaz Eghbalpour
Editorial Manager:
Dr. Mohammad Ali Saremi
Executive Manager:
Nayyere Moslehi
Frequency: Quarterly
Online ISSN: 2676-7236